Blueprint Medicines (FRA:2L9) EV-to-Revenue : 21.62 (As of May. 23, 2024)

Blueprint Medicines EV-to-Revenue Chart

Blueprint Medicines Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-Revenue		Get a 7-Day Free Trial					53.52	7.18	33.15	9.43	21.10

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															10.44	14.84	12.36	21.10	19.91

Competitive Comparison of Blueprint Medicines's EV-to-Revenue

For the Biotechnology subindustry, Blueprint Medicines's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blueprint Medicines's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's EV-to-Revenue falls into.

Blueprint Medicines EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Blueprint Medicines's EV-to-Revenue for today is calculated as:

Blueprint Medicines's current Enterprise Value is €5,632.3 Mil.
Blueprint Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €260.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Blueprint Medicines  (FRA:2L9) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Blueprint Medicines's PS Ratiofor today is calculated as:

Blueprint Medicines's share price for today is €95.04.
Blueprint Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.22.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Blueprint Medicines EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (FRA:2L9) Business Description